• Теги
    • избранные теги
    • Компании2973
      • Показать ещё
      Разное768
      • Показать ещё
      Страны / Регионы392
      • Показать ещё
      Международные организации48
      • Показать ещё
      Люди111
      • Показать ещё
      Показатели84
      • Показать ещё
      Формат38
      Издания19
      • Показать ещё
Gilead Sciences
21 июля, 23:03

Biotech Bull is Back: 4 Keys to Play It

The bleeding edge of science offers riches, but there are 4 disciplines you must apply to win in this wild west.

21 июля, 21:46

Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?

Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.

21 июля, 18:51

What to Expect from Keryx (KERX) this Earnings Season?

Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia (IDA) indication.

21 июля, 18:23

What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.

21 июля, 17:46

HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?

HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.

21 июля, 15:48

Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

20 июля, 18:31

Is a Beat in Store for Alexion (ALXN) this Earnings Season?

Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.

20 июля, 15:30

Is Gilead (GILD) Poised for a Beat This Earnings Season?

Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

Выбор редакции
19 июля, 17:15

Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

19 июля, 15:39

Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

Выбор редакции
15 июля, 11:00

Gilead (GILD) Application for HIV Drug Validated in EU

Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

15 июля, 11:00

Gilead (GILD) Application for HIV Drug Validated in EU

Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

Выбор редакции
14 июля, 21:35

Gilead (GILD) Application for HIV Drug Validated in EU

Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

14 июля, 21:35

Gilead (GILD) Application for HIV Drug Validated in EU

Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

14 июля, 16:59

3 ETFs Loaded with Positive ESP Stocks

Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank #1, 2 or 3 would lead to profits in investor portfolios.

14 июля, 16:30

The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals

The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals

13 июля, 21:31

5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates

The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.

13 июля, 16:30

The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire

The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire

13 июля, 15:13

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.